Seleccione otro país
Bienvenido a Lyxor España
Por favor, lea la información importante aquí incluida antes de continuar a nuestra página web

Información relevante 

Los Lyxor ETFs presentados en la página web de lyxoretf.com, pueden ser objeto de restricciones en lo que respecta a la inversión por determinadas personas o en determinados países, en virtud de las distintas regulaciones nacionales aplicables a dichas personas o en dichos países. Cualquier persona que acceda a esta página web desde una jurisdicción en la cual se aplican dichas restricciones tiene que informarse al respecto y observar dichas restricciones. Por consiguiente, le corresponde a usted asegurarse de que, efectivamente está autorizado a invertir en los Lyxor ETFs presentados en esta página web. Invirtiendo en estos productos, usted garantiza a Société Générale que está efectivamente autorizado a invertir. Inversores españoles se deben dirigir a www.lyxoretf.es

La información contenida en esta página web no constituye una oferta o invitación para adquirir o vender los productos aquí descritos a personas sometidas a  jurisdicciones donde:

(a) dicha oferta o invitación no esté autorizada;
(b) Lyxor Asset Management no esté cualificada para hacer dicha oferta o invitación;
(c)  sea ilícito hacer dicha oferta o invitación.

Los ETFs referidos en esta página web no han estado y no estarán registrados conforme al U.S Securities Act de1933, por lo tanto, no pueden ser ofertados ni vendidos en los EE.UU sin registro previo o solo en caso de excepción de registro conforme al  al Securities Act. Por consiguiente, los ETFs listados en esta página web no pueden ser vendidos a “U.S persons”, ni transferidos a los Estados Unidos a menos que dicha transacción esté sujeta a los requisitos de registro conforme a la ley Americana.

Esta página web es de carácter comercial y no de carácter legal. No se garantiza la exactitud, exhaustividad o pertinencia de la información aunque ha sido establecida a partir de fuentes consideradas como fiables.
La información presentada en esta página web se basa en información de mercado constada en un momento dado que puede variar con posterioridad a su publicación. El valor de reembolso de los Lyxor ETFs puede ser inferior al montante de la inversión inicial. En el peor de los casos, los inversores podrían perder hasta la totalidad de su inversión, por lo que se recomienda a los inversores consultar la sección« factores de riesgo » del folleto del producto. El precio de algunos Lyxor ETFs puede ser sensible a riesgos de tipo de cambio entre la cotización del ETF y/o la divisa del índice y/o la divisa del componente del índice.

Todos los LyxorETFs presentados en esta página web han sido aprobados por la “Autorité des Marchés Financiers (AMF)” y son objeto de un folleto aprobado por la AMF y pasaporteado en la CNMV conforme a la Directiva 2003/71/CE. Dichos folletos están disponibles en esta página Web.

La documentación relativa a los Lyxor ETFs preverá métodos de ajuste y de sustitución para tener en cuenta que consecuencias tendría cualquier suceso extraordinario que afecte a uno o varios de los subyacentes de estos productos.

Antes de invertir en un Lyxor ETF, usted debe hacer su propia valoración del riesgo desde un punto de vista legal, fiscal y  contable, sin depender exclusivamente de la información que le proporcionamos y consultando, si lo estima necesario, sus propios asesores en la materia o cualquier otro asesor independiente.

El inversor de ETFs estará expuesto a los siguientes factores de riesgo: Riesgo de pérdida del capital invertido, al no existir ninguna garantía, como consecuencia de un movimiento desfavorable del Índice de Referencia, Riesgo de que el objetivo de gestión solo se cumpla parcialmente, Riesgo de contrapartida como resultado de la utilización de los instrumentos financieros (OTC) formalizados con un establecimiento de crédito. Se recomienda a los inversores que consulten la sección del folleto antes de invertir.

En la medida en que cumpla con la legislación aplicable, ninguna entidad del Grupo Société Générale acepta responsabilidad alguna por las consecuencias financieras o de cualquier otra naturaleza que resulten de la inversión en este producto.

Utilizamos las Cookies para asegurar el correcto funcionamiento de nuestro sitio web, y para recopilar datos estadísticos sobre usuarios de modo que podamos mejorar el sitio web. Si continúa navegando por este sitio web usted aceptará nuestro uso de las Cookies.Para más información o para modificar sus preferencias sobre CookiesHaga click aquí
24 feb 2020

The coronavirus outbreak highlights a better way to invest in China

The outbreak and spread of a coronavirus from the central Chinese city of Wuhan has triggered a risk-off global mood. Aside from the human cost of the illness, many of the world’s biggest companies base parts of their supply chain in China, and some are warning of decreased output and revenue due to supply-chain disruption. Markets shuddered in early February but are proving resilient as the month goes on. History suggests that any further market falls may present an opportunity for long-term investors.

What’s happened?

  • Global markets have had a turbulent few weeks as investors digested the impact of the Wuhan coronavirus, dubbed Covid-19. Globally, there have been 73,332 cases confirmed of this variant of coronavirus, and more than 2,000 deaths.  The human impact of the coronavirus has been largely confined to the Asia-Pacific region, but the commercial ramifications are already being felt across the globe, particularly in the tech and automotive sectors, as they undergo considerable supply-chain disruptions.
  • Among the highest-profile companies to report disruption from the virus are Apple – which has cut its sales expectations for Q2 2020 blaming store and factory closures – and South Korean tech company Samsung, which has been flying and sailing smartphone components into neighbouring Vietnam from China, rather than driving freight across the restricted land border between the countries. 
  • EM investors in the MSCI Emerging Markets ex China Index have been partially protected from the recent sell-off, as the index has been far less volatile than its broad EM counterpart. More on this below. 

What’s next?

  • Investor confidence is likely to continue to rise and fall over the coming weeks. Many observers believe that China has learned lessons from previous pandemics and is now much better placed to contain the latest outbreak. Although estimates for Q1 growth are declining, most expect the economy to bounce back from the damage done by the virus, encouraging for the longer-term outlook for multiple sectors even with short-term disruptions. The economic growth forecast for 2020 is estimated to be around 5.5%, down from 5.9% last month.1
  • Global sectors exposed to domestic Chinese growth remain vulnerable. Many businesses have shuttered temporarily for health and safety reasons. Any business involving face-to-face transactions, such as food and drink, and airlines, are particularly vulnerable. Chinese authorities are now considering direct cash infusions or mergers for the hobbled airline industry, as daily nationwide travel remains a fifth of its usual level for this time of the year. Following several high-profile outbreaks aboard cruise ships, companies operating in this industry will also remain under pressure. 
  • Given the high number of companies with parts of their supply chain in China, there are likely to further knock-on effects announced on earnings calls for affected businesses. The tech industry may face short-term disruption, but this should have little lasting impact on tech spending in 2020. The outlook looks worse for the auto sector, which faces challenges from both the decline in domestic demand and China’s position as a key parts supplier to global auto-makers. 
  •  Viral outbreaks develop in unpredictable ways and there may be more bumps in the road over the coming weeks and months. The focus will be on China’s battle to contain Covid-19 and how the economy holds up after the extended shutdowns in the country. Further policy measures aimed at supporting activity are expected over the coming weeks. 

Viral outbreaks: What history tells us

  • After nearly two decades of dealing with mutant viruses (e.g. the 2002/3 SARS scare), Asia has developed the infrastructure and ability needed to better contain the cross-border transmission of viruses. Many observers compare the coronavirus to the 2003 SARS epidemic. Although the Covid-19 virus is genetically similar to SARS, it appears milder in terms of illness and case fatality rate. Another related virus, known as MERS-CoV, has been spreading since 2012 and has led to death in 34% of the 2,499 cases recorded. 
  • By contrast, an estimated 50 million people died in the 1918 Spanish flu pandemic that had a case-fatality rate of less than 5% but infected up to a third of the world’s population. Worst-case scenarios for Covid-19 should use the Asian Flu outbreak of 1957-58 (2 million deaths) or Hong Kong Flu of 1968-69 (1 million deaths) as a base case.
  • SARS had a time-limited negative economic impact. Visitor arrivals and retail sales stabilised within three months of the outbreak being contained.2 The history of SARS and avian flu outbreaks in China suggests that market dips may present an opportunity to buy risk assets at temporarily discounted levels.
  • Research conducted over recent years (e.g. by CDC Atlanta, and the World Bank) suggests that an outbreak like that of 1968-9 would today cause excess deaths in the range of 2 million to 7.4 million, with a GDP loss of $100-200bn for the US and around $550bn for all high-income countries taken together. 
  • Although using history as a template for projections can be useful, China is a much bigger player in the global economy and financial markets now than it was 17 years ago during the SARS outbreak. The Chinese share of global exports has more than tripled since the start of the millennium.3 In 2003, China accounted for 8% of the MSCI Emerging Markets index; today that figure is over 34%.4
  • We believe an allocation to Chinese equities should be managed independently of a broader emerging equities portfolio. Adopting such an approach enables investors to take greater exposure to other markets with improving fundamentals and vary their allocation to China depending on the prevailing market conditions. More volatility for Chinese equities can be expected over the weeks ahead.
  • The volatility profiles of the MSCI EM and MSCI EM ex-China have been very different since the beginning of the outbreak, even though the two indices have fallen by similar amounts. The chart below shows that the volatility of the MSCI EM ex-China has been much lower relative to that of the MSCI EM in recent weeks than it has historically.

MSCI chart

1Source: Bloomberg consensus data as at 19/02/2020

2Source: Asian Development Bank, Economics Paper Working Series, October 2019. https://www.adb.org/sites/default/files/publication/530216/ewp-591-sars-epidemic-2003-economic-costs.pdf

3Source: WTO, World Trade report 2019, November 2019 https://www.wto.org/english/res_e/reser_e/wtr2019_wtr_in_depth.pdf

4Source: MSCI. Data as at 31/01/2020.

Scenarios and related products

Adverse scenario: Cover your bases
 

Source : Lyxor International Asset Management, TER & AuMs correct as at 23/01/2020

Positive scenario: Position for market rebound
 

Source : Lyxor International Asset Management, TER & AuMs correct as at 23/01/2020.

Risk Warning

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on www.lyxoretf.com, and upon request to client-services-etf@lyxor.com.

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website www.lyxoretf.com/compliance.

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin